Phathom PharmaceuticalsPHAT
PHAT
About: Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Employees: 427
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
33% more call options, than puts
Call options by funds: $915K | Put options by funds: $688K
31% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 36
5% less funds holding
Funds holding: 144 [Q4 2024] → 137 (-7) [Q1 2025]
5.58% less ownership
Funds ownership: 97.51% [Q4 2024] → 91.94% (-5.58%) [Q1 2025]
14% less funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 6 (-1) [Q1 2025]
19% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 31
26% less capital invested
Capital invested by funds: $541M [Q4 2024] → $401M (-$140M) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
46%
downside
Avg. target
$16.40
79%
upside
High target
$28
205%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Craig-Hallum Chase Knickerbocker | 85%upside $17 | Buy Maintained | 9 Jun 2025 |
HC Wainwright & Co. Matthew Caufield | 118%upside $20 | Buy Reiterated | 9 Jun 2025 |
Needham Joseph Stringer | 205%upside $28 | Buy Maintained | 6 Jun 2025 |
Goldman Sachs Paul Choi | 46%downside $5 | Neutral Maintained | 2 May 2025 |
Guggenheim Yatin Suneja | 31%upside $12 | Buy Maintained | 2 May 2025 |
Financial journalist opinion
Based on 4 articles about PHAT published over the past 30 days
Positive
Seeking Alpha
2 weeks ago
Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism
VOQUEZNA's FDA exclusivity through 2032 and superior efficacy in GERD and H. pylori create a strong competitive moat in a $3.2B+ market. Rapid commercial uptake, robust DTC marketing, and >80% insurance coverage have driven $55M+ first-year sales and 390,000+ prescriptions. Discounted cash flow analysis supports a $14/share price target (43% upside potential), with near-term catalysts in sales growth, EU partnerships, and pipeline expansion.
Neutral
GlobeNewsWire
2 weeks ago
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Anne Marie Cook as Chief Legal Officer and Corporate Secretary, the Company's Board of Directors has approved the grant of inducement awards.
Neutral
GlobeNewsWire
2 weeks ago
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Anne Marie Cook, J.D.
Neutral
GlobeNewsWire
3 weeks ago
Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032
FLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the U.S. Food and Drug Administration (FDA) has updated the Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”) to accurately reflect the full 10-year period of non-patent New Chemical Entity (NCE) exclusivity for VOQUEZNA® (vonoprazan) 10 mg and 20 mg tablets.
Positive
Seeking Alpha
1 month ago
Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy
I'm bullish on Phathom Pharmaceuticals, Inc. after the FDA granted 10-year exclusivity to their flagship GI drug, Voquezna, giving them near-monopoly status. For those who don't know, this is a big deal because the FDA doesn't grant exclusivity rights often. Voquezna's prescription growth is surging, now with 390,000 fills and 127,000 in Q1 2025 alone, which is driving strong revenue momentum.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade
The consensus price target hints at a 107.4% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
1 month ago
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom's Citizen Petition filed on December 11, 2024 and communicated the Agency's intention to correct the Orange Book to recognize the proper 10 years of New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets, extending through May 3, 2032.
Neutral
GlobeNewsWire
1 month ago
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that the company is scheduled to participate in the following investor conferences in May and June: H.C.
Negative
Zacks Investment Research
2 months ago
After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT)
Phathom Pharmaceuticals (PHAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Neutral
GlobeNewsWire
2 months ago
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, the Company's Board of Directors has approved the grant of inducement awards.
Charts implemented using Lightweight Charts™